These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16148601)

  • 1. Modulation of 24-h blood pressure profiles: a new target for treatment?
    Palatini P; Parati G
    J Hypertens; 2005 Oct; 23(10):1799-801. PubMed ID: 16148601
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of non-dipper hypertension with bedtime administration of valsartan.
    Hermida RC; Calvo C; Ayala DE; Fernández JR; Covelo M; Mojón A; López JE
    J Hypertens; 2005 Oct; 23(10):1913-22. PubMed ID: 16148616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VALUE in hypertension treatment.
    Berk BC; Bisognano JD
    Curr Hypertens Rep; 2004 Dec; 6(6):411-3. PubMed ID: 15527682
    [No Abstract]   [Full Text] [Related]  

  • 4. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension.
    Minami J; Ohno E; Furukata S; Ishimitsu T; Matsuoka H
    J Hum Hypertens; 2009 Oct; 23(10):683-6. PubMed ID: 19369955
    [No Abstract]   [Full Text] [Related]  

  • 5. Blood-pressure reduction with LCZ696.
    Waeber B; Feihl F
    Lancet; 2010 Apr; 375(9722):1228-9. PubMed ID: 20236699
    [No Abstract]   [Full Text] [Related]  

  • 6. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; López JE
    Hypertension; 2005 Oct; 46(4):960-8. PubMed ID: 16144987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; Domínguez MJ; Covelo M; Fernández JR; Mojón A; López JE
    Hypertension; 2003 Sep; 42(3):283-90. PubMed ID: 12874091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuable lessons from VALUE.
    Hedner T; Kjeldsen SE; Himmelmann A
    Blood Press; 2004; 13(4):196-7. PubMed ID: 15581332
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
    Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR
    Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients.
    Eguchi K; Kario K; Hoshide Y; Hoshide S; Ishikawa J; Morinari M; Ishikawa S; Shimada K
    Am J Hypertens; 2004 Feb; 17(2):112-7. PubMed ID: 14751651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
    Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
    Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
    Julius S; Weber MA; Kjeldsen SE; McInnes GT; Zanchetti A; Brunner HR; Laragh J; Schork MA; Hua TA; Amerena J; Balazovjech I; Cassel G; Herczeg B; Koylan N; Magometschnigg D; Majahalme S; Martinez F; Oigman W; Seabra Gomes R; Zhu JR
    Hypertension; 2006 Sep; 48(3):385-91. PubMed ID: 16864741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts.
    Sica DA
    Hypertension; 2006 Sep; 48(3):362-3. PubMed ID: 16864742
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
    White WB; Lacourciere Y
    J Hypertens; 2004 Oct; 22(10):2035-6; author reply 2036-8. PubMed ID: 15361777
    [No Abstract]   [Full Text] [Related]  

  • 19. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hope in Life and Value of blood pressure control.
    Ruilope LM; Segura J
    J Hypertens; 2004 Dec; 22(12):2265-6. PubMed ID: 15614017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.